Open an account

BioLife Solutions

BLFS · NASDAQ

Price unavailable right now.

No price history for this range.

About BLFS

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 155 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The firm's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Employees
155
Headquarters
Bothell, Washington
Listed
Nov 22, 1989
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
biolifesolutions.com

BLFS key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 6 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 9 analystsAvg $31.91
Low
$31.31
High
$34.65

BLFS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 286.1% on average.

  1. Q3 FY24: reported -$0.04 per share against an estimate of -$0.0889
  2. Q4 FY24: reported $0.26 per share against an estimate of -$0.0656
  3. Q1 FY25: reported -$0.01 per share against an estimate of -$0.0539
  4. Q2 FY25: reported -$0.01 per share against an estimate of -$0.0364
  5. Q3 FY25: reported $0.01 per share against an estimate of -$0.0119
  6. Q4 FY25: reported $0.22 per share against an estimate of -$0.0221
  7. Q1 FY26: reported $0.02 per share against an estimate of $0.0204
  8. Q2 FY26: reported $0.04 per share against an estimate of $0.034

BLFS news

  • Press releasePRNewswire

    Freshworks Set to Join S&P SmallCap 600

  • Press releasePRNewswire

    Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

  • Press releaseBusiness Wire

    BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    BioLife Solutions Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--LXP, BLFS, PSNL, and FNWD

  • Press releasePRNewswire

    Are NG, BLFS, NRIM Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Similar companies

Companies in the same industry as BioLife Solutions

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.